NCT02831348 Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases Status COMPLETED Phase N/A
NCT02823470 A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation Status TERMINATED Phase PHASE4
NCT02810691 The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis Status COMPLETED Phase NA
NCT02807415 ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor Status COMPLETED Phase N/A
NCT02803944 Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years Status COMPLETED Phase N/A
NCT02802839 Virtual Reality for the Reduction of Pain During Venipuncture in Children With CF Status UNKNOWN Phase NA
NCT02797132 Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del Status COMPLETED Phase PHASE3
NCT02776098 Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance Status COMPLETED Phase N/A
NCT02769637 Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF) Status TERMINATED Phase N/A
NCT02767297 Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis Status COMPLETED Phase PHASE1/PHASE2
NCT02759562 Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis Status TERMINATED Phase PHASE2
NCT02753374 Registry Study on Cystic Fibrosis in Chinese Children Status NOT_YET_RECRUITING Phase N/A
NCT02750722 Exercise and Oscillatory Positive Expiratory Pressure Therapy in Cystic Fibrosis Status COMPLETED Phase NA
NCT02750501 Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study Status COMPLETED Phase NA
NCT02748798 Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders Status TERMINATED Phase EARLY_PHASE1
NCT02742519 A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation Status TERMINATED Phase PHASE3